Preclinical evaluation of a phosphorothioate oligonucleotide in the retina of rhesus monkey

Laboratory Investigation

Volumn 82, Issue 2, 2002, Pages 167-182

  Shen, Wei Yong ^a   Garrett, Kerryn L ^b   Wang, Chang Guan ^c   Zhang, Kun ^c   Ma, Zhi Zhong ^c   Constable, Ian J ^a   Rakoczy, P Elizabeth ^a  

^a LIONS EYE INSTITUTE   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c General Hospital of Chinese People s Liberation Army   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

DS 135; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DNA FLANKING REGION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG UPTAKE; FLUORESCENCE ANGIOGRAPHY; GENE OVEREXPRESSION; GENE TARGETING; HAZE; HUMAN; INCIDENCE; NONHUMAN; PRIORITY JOURNAL; RAT; RETINA; RETINA DEGENERATION; RETINA MACULA AGE RELATED DEGENERATION; RHESUS MONKEY; SUBRETINAL NEOVASCULARIZATION; TRANSLATION INITIATION;

ANIMALS; BASE SEQUENCE; CHOROIDAL NEOVASCULARIZATION; DNA PRIMERS; DRUG EVALUATION, PRECLINICAL; LASER COAGULATION; MACACA MULATTA; ORGANOPHOSPHORUS COMPOUNDS; RETINA; THIONUCLEOTIDES;

EID: 0036172573     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: 10.1038/labinvest.3780409     Document Type: Article

References (45)

1. Regulatory considerations for oligonucleotide drugs: Updated recommendations for pharmacology and toxicology studies
2. Age related macular degeneration
3. Retinal and choroidal neovascularization
4. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration
5. Inhibition of human cytomegalovirus replication in a human retinal epithelial cell model by antisense oligonucleotides
6. Disposition and toxicity of a mixed backbone antisense oligonucleotide, targeted against human cytomegalovirus, after intravitreal injection of escalating single doses in the rabbit
7. Evaluation of retinal toxicity and efficacy of anticytomegalovirus and anti-herpes simplex virus antiviral phosphorothioate oligonucleotides ISIS 2922 and ISIS 4015
8. Photodynamic therapy with verteporfin for age-related macular degeneration
9. In vivo use of oligonucleotides to inhibit choroidal neovascularisation in the eye
10. In vivo delivery of phosphorothioate oligonucleotides into murine retina
11. Modification of phosphorothioate oligonucleotides yields potent analogs with minimal toxicity for antisense experiments in the CNS
12. Two Independent internal ribosome entry sites are involved in translation initiation of vascular endothelial growth factor mRNA
13. Effects of photody namic therapy using verteporfin on experimental choroidal neovascularization and normal retina and choroid up to 7 weeks after treatment
14. Expression of vascular endothelial growth factor in experimental choroidal neovascularization
15. VEGF is major stimulator in model of choroidal neovascularization
16. Pharmacokinetics of an antisense oligonucleotide injected intravitreally in monkeys
17. Pharmacokinetics of a potential human cytomegalovirus therapeutic, a phosphorothioate oligonucleotide after intravitreal injection in the rabbit
18. Plasma VEGF and soluble VEGF receptor FLT-1 in proliferative retinopathy: Relationship to endothelial dysfunction and laser treatment
19. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes
20. Confidence intervals, power calculation, and sample size estimation for the squared multiple correlation coefficient under the fixed and random regression models: A computer program and useful standard tables
21. The model of development of vascular system of the retina, with some observation on its significance for certain retinal disease
22. Role of hypoxia and extracellular matrix-integrin binding in the modulation of angiogenic growth factors secretion by retinal pigmented epithelial cells
23. Phosphorothioate oligonucleotides induction into experimental choroidal neovascularization by HVJ-liposome system
24. Transgenic mice with increased expression of vascular endothelial growth factor in the retina: A new model of intraretinal and subretinal neovascularization
25. Basic fibroblast growth factor is neither necessary nor sufficient for the development of retinal neo-vascularization
26. Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization
27. Targeted delivery of an antisense oligonucleotide in the retina: Uptake, distribution, stability, and effect
28. Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy
29. The development of an experimental model of subretinal neovascularization in disciform macular degeneration
30. Intrachoroidal neovascularization in transgenic mice overexpressing vascular endothelial growth factor in the retinal pigment epithelium
31. Inhibition of diclofenac formulated in hyaluronan on angiogenesis in vitro and its intraocular tolerance in the rabbit eye
32. Dynamics of phosphorothioate oligonuc eotides in normal and laser photocoagulated retina
33. Expression of cell adhesion molecules and vascular endothelial growth factor in experimental choroidal neovascularisation in the rat
34. Treatment options in subfoveal choroidal neovascularization secondary to age-related macular degeneration
35. Effects of intraocular or systemic administration of neutralizing antibody against vascular endothelial growth factor on the murine experimental model of retinopathy
36. Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization
37. Antisense oligonucleotides as therapeutic agents: Is the bullet really magical?
38. Translation of vascular endothelial growth factor mRNA by internal ribosome entry: Implications for ranslation under hypoxia
39. Reversible bull's-eye maculopathy associated with intravitreal fomivirsen therapy for cytomegalovirus retinitis
40. Submacular surgery trials randomized pilot trial of laser photocoagulation versus surgery for recurrent choroidal neovascularization secondary to age-related macular degeneration: I. Ophthalmic outcomes: Submacular surgery trials pilot study report number 1
41. Submacular Surgery Trials randomized pilot trial of laser photocoagulation versus surgery for recurrent choroidal neovascularization secondary to age-related macular degeneration: II Quality of life outcomes: Submacular Surgery Trials Pilot Study Report Number 2
42. Inhibition of experimental choroidal neovascularization by over-expression of tissue inhibitor of metalloproteinases-3 in retinal pigment epithelium cells
43. Vascular endothelial growth factor expression in choroidal neovascularisation in rat
44. Pathophysiology of age-related macular degeneration
45. Mitogenesis and retinal pigment epithelial cell antigen expression in the rat after krypton laser photocoagulation